Bone Therapeutic Area, UCB Pharma, Slough, United Kingdom.
J Mol Endocrinol. 2019 Feb 1;62(2):R167-R185. doi: 10.1530/JME-18-0176.
The discovery that two rare autosomal recessive high bone mass conditions were caused by the loss of sclerostin expression prompted studies into its role in bone homeostasis. In this article, we aim to bring together the wealth of information relating to sclerostin in bone though discussion of rare human disorders in which sclerostin is reduced or absent, sclerostin manipulation via genetic approaches and treatment with antibodies that neutralise sclerostin in animal models and in human. Together, these findings demonstrate the importance of sclerostin as a regulator of bone homeostasis and provide valuable insights into its biological mechanism of action. We summarise the current state of knowledge in the field, including the current understanding of the direct effects of sclerostin on the canonical WNT signalling pathway and the actions of sclerostin as an inhibitor of bone formation. We review the effects of sclerostin, and its inhibition, on bone at the cellular and tissue level and discuss new findings that suggest that sclerostin may also regulate adipose tissue. Finally, we highlight areas in which future research is expected to yield additional insights into the biology of sclerostin.
这一发现促使人们研究骨稳态中骨硬化蛋白的作用,因为两种罕见的常染色体隐性高骨量疾病是由骨硬化蛋白表达缺失引起的。本文旨在通过讨论骨硬化蛋白减少或缺失的罕见人类疾病、通过遗传方法对骨硬化蛋白进行操作以及用中和骨硬化蛋白的抗体在动物模型和人类中进行治疗,来汇集与骨硬化蛋白相关的大量信息。这些发现共同证明了骨硬化蛋白作为骨稳态调节剂的重要性,并为其作用的生物学机制提供了有价值的见解。我们总结了该领域的现有知识状况,包括对骨硬化蛋白对经典 WNT 信号通路的直接作用以及骨硬化蛋白作为骨形成抑制剂的作用的当前理解。我们综述了骨硬化蛋白及其抑制物在细胞和组织水平上对骨骼的影响,并讨论了新发现,表明骨硬化蛋白可能还调节脂肪组织。最后,我们强调了未来研究有望进一步深入了解骨硬化蛋白生物学的领域。